Eliezer Katz

Eliezer Katz's Title

Eliezer Katz currently holds the prestigious position of Chief Medical Officer at Eledon Pharmaceuticals. His extensive background in clinical development and transplantation surgery uniquely positions him to lead Eledon's medical and clinical strategies. Katz's role involves overseeing the development of new therapies and ensuring regulatory compliance, leveraging his extensive experience in the field.

Eliezer Katz's Company

Eledon Pharmaceuticals is where Eliezer Katz brings his expertise as Chief Medical Officer. Eledon focuses on developing innovative treatments for patients with autoimmune diseases, organ transplantation needs, and other serious conditions. Katz's leadership is pivotal in driving forward the company's mission to transform patient care through cutting-edge medical solutions.

Eliezer Katz's Experience

Eliezer Katz has a robust career spanning over two decades. Before joining Eledon Pharmaceuticals, he served as Chief Medical Officer at eGenesis, and as Vice President of Clinical Development at Viela Bio, later acquired by Horizon Therapeutics. During his tenure, he led the clinical development and regulatory approval of UPLIZNA® (inebilizumab) for multiple autoimmune indications. His earlier roles include Senior Director positions at MedImmune Inc. and Pfizer, where he focused on clinical development and transplantation.

Eliezer Katz's Education and Expertise

Eliezer Katz earned his M.D. from Hadassah Hebrew University Medical School in Jerusalem, a foundational step that propelled his career in medicine. His expertise is particularly notable in the areas of transplantation and clinical development. Katz has held academic roles such as an associate professor of surgery and director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA. His academic and professional journey underscores his deep commitment to advancing medical science and patient care.

Eliezer Katz's Achievements

Among Eliezer Katz's numerous achievements is his leadership in the clinical development of inebilizumab for autoimmune conditions, culminating in the regulatory approval of UPLIZNA® (inebilizumab). His tenure as director of the abdominal transplantation division at Integris Baptist Medical Center and his role in academic settings highlight his contributions to both clinical practice and medical education. Katz's work has had a profound impact on the fields of transplantation and autoimmune disease treatment.